Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Core Viewpoint - Pharma Equity Group A/S (PEG) will terminate its agreement with Danske Bank as liquidity provider effective from January 1, 2026, and will not enter into a new agreement, focusing instead on direct communication and Investor Relations activities to create shareholder value [1][2]. Group 1: Termination of Agreement - The agreement with Danske Bank will end on January 1, 2026, with the last trading day being December 31, 2025 [1][3]. - The decision not to engage a new liquidity provider is based on management's assessment that direct communication and Investor Relations will yield greater value for shareholders [2]. Group 2: Impact on Liquidity - The termination of the liquidity provider agreement may technically affect PEG's share liquidity, including the bid-ask spread, due to the absence of an external party to provide bid and ask quotes [3]. Group 3: Company Overview - Pharma Equity Group A/S is an investment and development company focused on Life Science, listed on Nasdaq Copenhagen, and aims to develop early-stage innovation projects in pharmaceuticals and MedTech, particularly from Scandinavian research institutions [4]. - The company seeks to build a balanced portfolio that supports long-term growth and creates value for patients, healthcare systems, and investors through strategic capital allocation and strong governance [4].